Advertisement
Advertisement
February 3, 2022
Koya Medical Secures Funding for Active Compression Therapies for Lymphedema and Venous Disorders
February 3, 2022—Koya Medical announced the close of a $26 million Series B financing. Proceeds from the financing will be used to accelerate the expansion and commercialization of the company’s Dayspring active compression system.
The company will also use the funds to continue to advance the Dayspring platform and clinical research programs to pursue additional indications for lymphedema and venous disorders.
According to the company, Dayspring is FDA 510(k) cleared to treat lymphedema and other similar conditions that impact lymphatic flow in the upper and lower extremities. Dayspring is a wearable active compression treatment that enables movement and mobility.
The round was led by 3x5 Partners, along with new investors including Asahi Kasei Ventures, Cadence Healthcare Ventures, and existing investors Arboretum Ventures and Scientific Health Development, among others, advised Koya Medical.
Advertisement
Advertisement
